PSA Density Plus MRI May Improve Detection of Clinically Significant Prostate Cancer
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis.
All articles by John Schieszer, MA
4Kscore May Help Predict Adverse Pathology at Radical Prostatectomy
In a study, a higher 4Kscore was significantly associated with a 16% greater risk of biochemical recurrence of prostate cancer following radical prostatectomy.
Metformin Found Not to Prevent Prostate Cancer
A study looking at the effect of genetic variations on the pharmacologic activity of metformin found that use of the drug was associated with an increased risk of prostate cancer overall and of high-grade prostate cancer.
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC
In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.
Genomic Alterations Linked to Outcomes in mCSPC
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
Prostate MRI Improves Confirmatory Biopsy Sensitivity
MRI-guided confirmatory prostate biopsies more accurately detects grade progression among men on active surveillance for prostate cancer compared with TRUS-guided systematic biopsies alone.
AI Could Improve Prostate Cancer Brachytherapy
Enhanced deep-learning models have the potential to streamline prostate cancer brachytherapy treatment planning, according to investigators.
Imaging Needed to Identify Bone Metastases in Advanced PCa
Bone imaging cannot be safely omitted in advanced prostate cancer cases because no PSA level combined with T stage and Gleason Grade Group can accurately rule in bone metastases, a new study found.
Novel Antiandrogens and Cognitive Function
The authors of a recent review say they believe only a fraction of the men on androgen receptor-directed therapies who experience cognitive impairment report it.
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations
For decades, it has been known that the mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer, but a new prospective cohort study provides the strongest evidence to date that these mutations are associated with the development of prostate cancer (PCa). The BRCA2 mutation appears…
-
Loading...
-
Loading...
Next post in Prostate Cancer
